Navigation Links
Raloxifene Cuts Risk of Certain Type of Breast Cancer
Date:6/11/2008

And the benefits weren't limited to high-risk women, study finds

WEDNESDAY, June 11 (HealthDay News) -- A drug already approved to reduce the risk of breast cancer in high-risk women also seems to cut the risk for other women.

A new analysis finds that those who took raloxifene (Evista) regularly over a number of years were less likely to develop invasive estrogen-receptor (ER) positive breast cancer, compared with women who did not take the drug.

Raloxifene did not, however, cut the risk for noninvasive breast cancer or invasive ER-negative cancers.

"This is a reaffirmation that the drug raloxifene is a very powerful SERM [selective estrogen receptor modulator] for reducing the risk of invasive breast cancer," said Dr. Jay Brooks, chief of hematology/oncology at Ochsner Health System in Baton Rouge, La.

The study, published in the June 10 online issue of the Journal of the National Cancer Institute, was funded by Eli Lilly and Co., which makes Evista.

SERMs block the female hormone estrogen by binding to estrogen receptors; estrogen helps fuel the growth of some breast cancers. Raloxifene and other hormonal therapies have an "estrogenic tickle" effect, explained V. Craig Jordan, author of an accompanying editorial in the journal and vice president and research director for medical science at Fox Chase Cancer Center in Philadelphia. Jordan did some of the early laboratory research on raloxifene.

Raloxifene was originally developed to prevent and treat osteoporosis, and only later was found to help reduce the risk of invasive breast cancer in high-risk women.

The new study expands on the original results of the RUTH (Raloxifene Use for the Heart) trial, originally designed to see if raloxifene, which has cholesterol-lowering properties, could reduce the risk of dying from coronary heart disease.

The trial involved more than 10,000 postmenopausal women with coronary heart disease or at risk for the condition. Participants were randomly chosen to receive either daily raloxifene or a placebo and followed for a median of 5.6 years.

Raloxifene turned out not to have any effect on heart disease mortality risk, but it did reduce the risk of invasive breast cancer by 44 percent, which translates into 1.2 women per 1,000 treated for one year who were spared the agony of a breast cancer diagnosis.

The new analysis looked more specifically at raloxifene's effect on breast cancer and found a 55 percent lower incidence of invasive ER-positive tumors, but no effect on noninvasive breast cancer or invasive ER-negative breast cancer.

According to the study authors, these findings are consistent with results from other trials involving women without heart disease. This trial and others found an increased risk of blood clots and fatal strokes among women taking raloxifene, indicating that women need to weigh the risks and benefits of the drug.

Another question is how long to take raloxifene for breast cancer prevention, although the authors speculated that up to eight years might be safe and effective.

"We're learning more about this class of drugs, what works and what doesn't work," Jordan said. "[Raloxifene] is good for osteoporosis, no good for coronary heart disease, but breast cancer is inhibited."

More information

The U.S. National Cancer Institute has more on SERMs and how they work.



SOURCE: V. Craig Jordan, Ph.D., vice president and research director, medical science, Fox Chase Cancer Center, Philadelphia; Jay Brooks, M.D., chairman, hematology/oncology, Ochsner Health System, Baton Rouge, La.; June 10, 2008, Journal of the National Cancer Institute, online


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Raloxifene Safe for Women With Decreased Kidney Function
2. Consumers Urged to Avoid Certain Tomatoes Amid Salmonella Scare
3. Demonstrating the Value of Benchmarking in an Uncertain Economy
4. St. Jude finds young age may give survival advantage to children with certain brain tumors
5. Certain Tests in ERs Raise Cancer Risk for Some
6. Study Showed ALIMTA(R) (pemetrexed for injection) Improved Survival in Certain Types of Non-Small Cell Lung Cancer
7. Gypsum Wallboard from CertainTeeds Moundsville, W. Va., Plant and Roofing Shingles among Building Materials Donated to St. Jude Dream Home(R)
8. Regular prostate-specific antigen screening may be discontinued in certain elderly populations
9. Experimental drug shows promise in treating certain lymphomas
10. Study finds certain liver disease related to cardiovascular fitness
11. Womens Risk for a Certain Skin Cancer Varies by Geography
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... , ... Lake Park Dental is now accepting new patients with crooked teeth ... With the help of this highly-effective, yet convenient system, patients can straighten their teeth ... less pain. , Drs. Sarah Jockin, Nicole Morganti, Sara Spear and Elizabeth Dy, ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... unveiling cutting-edge birth defects research related to Zika virus during pregnancy, as well ... society for this important science. , The Teratology Society is ...
(Date:4/25/2017)... , ... April 25, 2017 , ... Saad B. Chaudhary, MD is committed to providing ... acute or chronic problems, I focus on preventative care with all my patients to alleviate ... any questions, always feel free to contact my office and my trained staff will assist ...
(Date:4/25/2017)... ... 25, 2017 , ... There is no better place in South Florida to ... in the May issue of Consumer Reports focused on heart health. , The ... during and after coronary bypass and aortic valve replacement procedures. , Consumer Reports ...
(Date:4/24/2017)... ... , ... Emmanuel College is introducing enhancements to its RN-to-BSN ... the fall of 2017, Emmanuel’s program will allow registered nurses (RN)s to earn a ... for as little as $14,528. These changes will enable nurses to complete their degree ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... OAKS, Calif. , April 19, 2017 /PRNewswire/ ... industrial buildings it is developing at Conejo Spectrum ... , to Atara Biotherapeutics, Inc. , ... with severe and life-threatening diseases that have been ... on allogeneic T-cell therapies for cancer, autoimmune and ...
(Date:4/18/2017)... , April 18, 2017 Cogentix Medical, Inc. ... providing the Urology, Uro/Gyn and Gynecology markets with innovative ... first quarter ended March 31, 2017 after the market ... The Company will host a conference call and webcast ... Tuesday, May 2, 2017 at 4:30 p.m. Eastern Time ...
(Date:4/18/2017)... April 18, 2017 Research and Markets has ... report to their offering. ... The global arthroscopy devices market to grow at a CAGR of ... Arthroscopy Devices Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
Breaking Medicine Technology: